Navigation Links
NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009
Date:3/2/2009

ANN ARBOR, Mich., March 2 /PRNewswire/ -- NanoBio Corp. announced today that it will present compelling new data highlighting key clinical and preclinical milestones in the development of its novel topical treatments for herpes labialis, onychomycosis and tinea capitis. The new data will be delivered in five presentations during the 2009 meeting of the American Academy of Dermatology in San Francisco, March 6-9, 2009.

In addition to the oral poster presentations listed below, the presentations will be available electronically at the kiosks provided by the AAD during the conference. NanoBio will also sponsor corporate booth # 5284, where information on the company's development programs for acne, herpes and antifungal products will be available.

Oral Poster Presentations

Saturday, March 7, 2009 -- Center 3

Poster # P2411, 10:20 a.m. -- Antifungal Activity and Mechanism of Action of NB-002, a Novel Topical Antifungal, Against the Major Pathogens of Onychomycosis

Poster # P2423, 12:20 p.m. -- Antifungal Activity of NB-002, a Topical Nanoemulsion, Against Rare Fungal Pathogens of Onychomycosis

Poster # P2505, 2:00 p.m. -- Investigator Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis

Poster # P2517, 4:00 p.m. -- Safety, Tolerability and Pharmacokinetics of Topical NB-001 (0.1%, 0.3% and 0.5%) for the Treatment of Recurrent Herpes Labialis

Sunday, March 8, 2009 - Center 1

Poster # P2114, 10:40 a.m. -- A Randomized, Double-Blind, Vehicle-Controlled Trial of Novel Topical Antifungal Nanoemulsion (NB-002) in Subjects With Distal Subungual Onychomycosis

About NanoBio

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.


'/>"/>
SOURCE NanoBio Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria
2. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
3. NanoBio Wins 2007 Michigan Innovation Award
4. MedThink Communications Retained by NanoBio Corporation
5. MHA Announces: Launch of New Website
6. National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs
7. Lilly Announces Leadership Changes
8. Availity Announces Support of Project SwipeIT
9. The Vitality Group Announces Expansion to Board of Directors
10. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
11. Boston Scientific Announces Election Of John Sununu To Its Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, ... to its patient care management module. Using this new feature, sleep physicians can ... been initiated on continuous positive airway pressure (CPAP), oral, or other forms of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
Breaking Medicine News(10 mins):
(Date:4/25/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 6086379. Please dial in 10 minutes prior to the scheduled start ... call will be available from May 9, 2017 at 11:30 a.m. ...
(Date:4/24/2017)... BOURNEMOUTH, England , April 24, 2017 /PRNewswire/ ... line development, today announced the addition of a ... for ,Validated In-situ Plate Seeding,). The VIPS has ... 96 and 384 well microplates as part of ... new system offers a simple and more reliable ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
Breaking Medicine Technology: